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Abstract
Background: Malaria in Zambia accounts for about 4 million clinical cases and 8 000 deaths
annually. Artemether-lumefantrine (ACT), a relatively expensive drug, is being used as first line
treatment of uncomplicated malaria. However, diagnostic capacity in Zambia is low, leading to
potentially avoidable wastage of drugs due to unnecessary anti malarial treatment.
Methods: A cost-effectiveness evaluation of the three current alternatives to malaria diagnosis
(clinical, microscopy and Rapid Diagnostic Tests- RDT) was conducted in 12 facilities from 4
districts in Zambia. The analysis was conducted along an observational study, thus reflecting
practice in health facilities under routine conditions. Average and incremental cost effectiveness
ratios were estimated from the providers' perspective. Effectiveness was measured in relation to
malaria cases correctly diagnosed by each strategy.
Results: Average cost-effectiveness ratios show that RDTs were more efficient (US$ 6.5) than
either microscopy (US$ 11.9) or clinical diagnosis (US$ 17.1) for malaria case correctly diagnosed.
In relation to clinical diagnoses the incremental cost per case correctly diagnosed and treated was
US$ 2.6 and US$ 9.6 for RDT and microscopy respectively. RDTs would be much cheaper to scale
up than microscopy. The findings were robust to changes in assumptions and various parameters.
Conclusion: RDTs were the most cost effective method at correctly diagnosing malaria in primary
health facilities in Zambia when compared to clinical and microscopy strategies. However, the
treatment prescription practices of the health workers can impact on the potential that a diagnostic
test has to lead to savings on antimalarials. The results of this study will serve to inform policy
makers on which alternatives will be most efficient in reducing malaria misdiagnosis by taking into
account both the costs and effects of each strategy.
Background
Malaria is a major public health problem in the world
where at least 3.2 billion people are at risk of the disease
annually [1]. The World Health Organisation (WHO) esti-
mates that 60% of the cases and 80% of malaria related
mortality occurs in Sub Sahara Africa (SSA) [2] an area
geographically defined as the hub of poverty.
In Zambia, the disease is endemic countrywide and about
95% of all cases are caused by the mostly deadly malaria
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parasite species, Plasmodium falciparum[3]. The Health
Management Information System (HMIS) estimates 4
million clinical cases and 8,000 deaths due to malaria
annually. It is against this background that in 2003, the
national antimalarial drug policy in Zambia was revised.
This led to the replacement of the failing chloroquine
(CQ) and Sulphadoxine-pyrimethamine (SP) with artem-
isinin-based combination therapy (ACTs) for the treat-
ment of uncomplicated malaria. Currently, ACTs have
been scaled up countrywide to treat uncomplicated cases
of malaria. ACTs have been reported to be highly effica-
cious in treating uncomplicated malaria and conse-
quently reducing the transmission of resistant genes [4,5].
Nonetheless, malaria diagnostic capacity plays a pivotal
role in correctly identifying malaria cases from non-
malaria cases. The use of an accurate diagnostic test, which
is determined by its sensitivity and specificity, would
imply that only true cases would be prescribed an antima-
larial. This would help in channelling antimalarial drugs
to those that need them and at the same time provide the
non-malaria cases an opportunity to be examined for
other causes of illness. However, this is a challenge for
Zambia where only 34% of the facilities have laboratory
facilities for microscopy services and of these only 60%
have functional laboratories [6]. Thus, most fevers are
being diagnosed clinically to be malaria. Integrated man-
agement of childhood illnesses (IMCI) guidelines are
being applied to ensure that other causes of fever in chil-
dren are excluded [7,8]. However, these guidelines have
been found to be misapplied, possibly because only 33%
of the frontline health workers have received IMCI train-
ing [9].
Coartem® (a fixed dose combination of Artemether- lume-
fantrine -AL), which is being used to treat uncomplicated
malaria in Zambia, is much more expensive than the
former monotherapies. Thus, the malaria drug budget in
Zambia has increased almost eight-fold from US$ 579,
300 in 2003 (when SP was the first line treatment) to US$
4,474,018 in 2005 (when AL was scaled up country wide).
Without malaria confirmation, it is difficult to exclude
fevers, which are not due to malaria, thus the true burden
of the disease proves difficult to quantify. This might be
lead to wastage of drugs on unnecessary treatment and
inappropriate patient management.
New technologies on malaria diagnosis have introduced
Rapid Diagnostic Tests (RDTs), which work on the princi-
ple of antigen detection methods. These immunochroma-
tographic dipsticks can be sensitive to two basic antigens
of the malaria parasites; the histidine-rich protein-2
(HRPII) or parasite lactate dehydrogenase (pLDH) [10].
These tests are now being thought of as a viable option for
defining malaria parasite presence in the patients sus-
pected of having malaria. RDTs, unlike microscopy, can
easily be used by any frontline health workers and do not
need extra infrastructure [11].
In this context, it is relevant to assess the diagnostic accu-
racy (intermediate outcome) with the economic implica-
tions of the available diagnostic techniques for malaria.
On the basis of cost effectiveness, the study seeks to chal-
lenge the current reliance on clinical diagnosis as opposed
to the introduction of malaria confirmatory diagnostic
methods in this era of ACTs.
Methods
Study design
This study evaluates the operational cost-effectiveness of
the three available options (clinical, microscopy and
RDTs) for diagnosis of malaria in light of ACTs as first line
treatment. This study was conducted from a public health
(or provider) perspective mainly because malaria services
in Zambia are provided free of charge (with the exception
of registration costs in urban centres). It was also assumed
that since each district implemented all the three strate-
gies, the indirect costs borne by patients would be similar
across diagnostic strategies. The study was conducted in
the context of the routine health facility operations as per
standard malaria treatment guidelines in Zambia. The
outcome measure, the proportion of cases correctly diagnosed
is an intermediate one. It includes cases found positive in
the presence of the condition and cases found negative in
the absence of the condition in relation to the total cases
diagnosed by each method.
Study population and period of evaluation
All malaria related visits (suspected or confirmed), which
occurred from March to November 2005 in the selected
12 facilities were included in the study. This timeline
allowed for the capture of both the low and high transmis-
sion seasons of malaria in Zambia. The method of diagno-
sis of each patient depended on the predetermined
diagnosis strategy (clinical, microscopy or RDT) assigned
to the facility prior to the commencement of the study.
However, the management of the patient and the type of
treatment administered was left to the health workers'
decision. In other words, in the case of laboratory or RDT
confirmation, the study team did not indicate a strict treat-
ment prescription rule based on the test result. Efforts
were made to ensure that all the health staffs at each facil-
ity were trained in data recording and use of RDTs (where
applicable) based on standard job aids and the national
malaria case management guidelines.
Study sites
In the four district selected for the study; Chingola (Cop-
perbelt Province), Kabwe (Central Province), Kalomo
(Southern Province) and Chongwe (Lusaka Province)
malaria is meso to hyper endemic. Three facilities in each
selected district were assigned one of each malaria diag-Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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nostic approaches: clinical, microscopy or RDTs, bringing
the total number of facilities studied to 12. These sites
were also part of the sentinel sites surveillance system for
malaria; this ensures that the different epidemiological
zones in Zambia were represented. Likewise, the districts
selected were part of larger study collecting information
on the "financial sustainability plan (FSP)" for scaling up
malaria control activities. This opportunity provided the
means of collecting quality and reliable data from these
facility registers under routine conditions.
Description of the interventions under comparison
Clinical Diagnosis of Malaria
This strategy is carried out for a trained health worker who
can diagnose malaria based on the signs and symptoms a
patient presents with. The minimal elements required for
clinical diagnosis are simply a thermometer (for measure-
ment of axillary temperature) and a weighing scale where
applicable. If temperature is above or equal to 37.5°C or
where a history of fever exists and malaria is suspected,
treatment is commenced and the patient returns home.
Thus it is possible for a trained health worker to exclude
fevers from malaria based on the patients' signs and symp-
toms. Cases clinically thought not to have a fever due to
malaria are considered 'negative'.
Microscopy Diagnosis of Malaria
Where microscopy facilities are available, a clinical officer
or nurse initially assesses patients. If malaria is suspected,
the patient is sent to the laboratory for malaria investiga-
tion. A laboratory technician or microscopists analyses the
patients' blood sample for malaria infection. The results
are recorded in the patients file and the patient is
instructed to return to the screening room with the labo-
ratory results. The clinician then prescribes treatment
based on both the laboratory result and the clinical pres-
entation of the patient at that time. This strategy required
optimal laboratory infrastructure, including a trained
microscopist or laboratory technician, a functional micro-
scope, reagents, electricity supply, water supply and other
consumables such as lancets, blood slides. Microscopy
diagnosis results are obtained after at least 30 minutes.
RDT Diagnosis of Malaria
A clinical officer or nurse initially assesses the patient,
once malaria is suspected; parasitological confirmation of
malaria infection is performed with an RDT. Depending
on the results, the clinician may then prescribe an antima-
larial. It should be noted here that the health worker per-
forms both the clinical assessment and the RDT test. This
is unlike microscopy facilities where laboratory personnel
are essential in the diagnosis of malaria. The minimum
requirements for this diagnostic strategy include: 1 RDT
kit (which contains a test dip stick, desiccant, sample
applicator, buffer solution and collection capillary tubes)
and a clinical officer or nurse (or Commissioned Daily
Employee in some rural areas) on how to use the RDTs.
Lancets, methylated spirit and cotton wool are some of
the supplies needed to be bought separately if they do not
come with the kit.
Data collection procedures
During the study period, all the patients suspected of malaria
were being recorded in the facility's outpatient malaria regis-
ters and received clinical or confirmatory diagnosis based on
the allocated method in that facility. In all the sites AL was
being used as first line treatment for malaria. Records were
kept for all the patients screened on the diagnostic strategy
(clinical, microscopy or RDT), test result (positive or nega-
tive), malaria type (uncomplicated or complicated), antima-
larial treatment given (quinine, SP or AL) and referrals. The
facility registers thus provided a basis for morbidity data col-
lection (malaria suspected outpatient visits and confirmed
malaria cases). Secondary data from published literature was
used to determine the sensitivity of clinical, microscopy and
RDTs in diagnosing malaria.
In the selected health facilities, three levels of supervision
were put in place to ensure data completeness and accu-
racy. The first level corresponded to the health facility
head to supervise daily and weekly patient data profiles,
district heath information officers in turn (second level)
supervised facility heads and conducted on spot check of
patient files and ensured they were consistent with
malaria registers. Finally, the central level teams super-
vised monthly data collection on site and on data entry
files.
Cost information was obtained from facilities, central level
sources and suppliers of commodities where applicable. The
ingredient approach combined with step-down approach to
costing was used to estimate average costs per month and per
year [12]. Data collection forms were developed to conduct
inventories on capital and recurrent costs related to malaria
diagnosis. Health staffs were also interviewed to get an opin-
ion on some of the resources required the daily management
of malaria patients. Financial reports, cash receipts, malaria
outpatient registers, district action plans, procurement units,
market prices of commodities and various data sources were
reviewed and triangulated to accurately measure and value
the resources used. Cost data, was obtained from various
expenditure points such as obtained from district or central
level sources, expenditure reports and market prices of
goods. The cost of distribution was estimated from main
government distributors and was added to the unit cost.
Capital costs
Capital resources (i.e. items which have a useful life of more
than one year) were annualised based on the replacement
value, its estimated useful life and the official discount rate
(5%) used in Zambia (MOH Planning Unit, Zambia per-
sonal communication). Capital costs comprise equipment,Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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vehicles and buildings. The allocation of capital costs to
malaria diagnosis was determined by estimating an alloca-
tion rate per facility. This was derived from malaria OPD uti-
lisation in relation to all the visits registered in the facility.
However, laboratory related capital costs were allocated
based on the number of analyses for malaria as a proportion
of the total laboratory analyses for all diseases.
Recurrent costs
Personnel costs were measured based on number and cat-
egories of each type of staff (nurse, clinical officer, medical
doctor, community health worker, etc) and their respec-
tive annual salaries. These were then allocated based the
utilisation of facilities by suspected malaria patients.
Shared recurrent costs such as supplies, and utilities were
valued using a step-down approach to costing and allo-
cated based on the facility utilisation by malaria patients.
However, costs unique to malaria (such as cost of the
diagnostic technique) were fully allocated as such. Dis-
tricts are also allowed up to 15% of their total expendi-
tures on administration costs (or overheads). Therefore in
the absence of a better sources of administrative expendi-
tures, it was assumed that on average, 15% of malaria
related expenditure would be on administrative costs such
as fuel, communications, cleaning materials, stationery
and other utilities. For simplicity, all other recurrent costs
(non-personnel or malaria specific) were termed over-
heads in this study. Table 1 summarises the various
assumptions and parameters used in the analysis of costs
and cases correctly diagnosed.
Outcome measures
Malaria diagnosis accuracy of each technique was evalu-
ated by its ability to increase cases correctly diagnosed
(true positives and true negatives) and the ability to
decrease cases incorrectly diagnosed (false positives and
false negatives). These were calculated from the total
number of patients screened, the screening results, the
underlying malaria prevalence and the sensitivity of the
diagnostic strategy used. A '2 x 2 Table' (which is based on
Bayesian theory applied on screening methodology) was
used to carry out these calculations.
The main outcome measure was the number and propor-
tion of malaria cases correctly diagnosed by each diagnos-
tic strategy. The sensitivity of each strategy was drawn
from evidence from the literature and weighted up accord-
ing to sample size and relevance for the Zambian setting.
Thus, sensitivity was used as the input parameter, whereas
specificity was an output variable. This is because sensitiv-
ity and specificity vary with prevalence, and the districts
under study had varying underlying prevalence as shown
in table 2. For clinical diagnosis, the sensitivity for two
sites (Kalilo and Kalonda) was assumed at 100%, because
almost all the suspected malaria visits were classified as
positive for malaria. For the remaining two clinical sites
(Chinyunyu and Natuseko), which at least reported on
some negative cases, the average sensitivity was assumed
at about 90%. These figures were similar to sensitivity
analysis from literature [13,14].
Microscopy is assumed to be the gold standard only under
ideal conditions. However, under routine conditions,
microscopy has been found to have sensitivity of 91% and
specificity of 71% [15] when compared to expert micros-
copy. Thus, the sensitivity rate from these findings was
used to determine cases correctly diagnosed through
microscopy.
For RDT tests, the weighted average of the sensitivity was
calculated from studies that used Paracheck Pf brand and
performed field evaluations by comparing RDT to expert
microscopy [16,17]. The sample size of each study deter-
mined the weight used in the calculation of the average
sensitivity. The two studies were selected based on clinical
and methodological similarities. In this way, it was hoped
that statistical heterogeneity would be reduced. The
weighted average sensitivity for RDT was 95.36%.
The underlying prevalence in the districts facilities was
obtained from survey data conducted by the NMCC. These
prevalence values are assumed to approximate the true
annual prevalence of malaria among patients suspected of
malaria seeking care at the facility. An important aspect of
these surveys is that they incorporate the 2–9 years who are
the standard group for estimating malaria parasite preva-
lence [9]. In the case of Chongwe, Kabwe and Chingola, the
prevalence figures were obtained from the 2005 parasitolog-
ical surveys, whereas for Kalomo, the 2004 figure was used in
the absence of any latest estimates (see table 1).
Thus based on the sensitivity of each strategy and the
underlying prevalence in each district, the following equa-
tions (derived from Bayesian theory) were used to esti-
mate true positives, false positives, true negatives and false
negatives and consequently the cases correctly diagnosed.
1. True positives = prior prevalence * visits * sensitivity
2. False positives = found positive - true positives
3. False negatives = (prior prevalence * total visits) -
true positives
4. True negatives = found negative - false negatives
5. Cases correctly diagnosed = true positives + true
negatives
6. Accuracy = number of cases correctly diagnosed/
total visits.Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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Average Cost Effectiveness and Incremental Cost Effectiveness 
Analysis
After establishing the costs and consequences of each
alternative, the average cost per case diagnosed as well as
the average cost per case correctly diagnosed was calcu-
lated for each strategy. Average costs were calculated with
and without treatment costs. However, the relevant cost
effectiveness ratio has been defined as the average cost per
case correctly diagnosed and treated, as follows:
Where,
Cd = Cost of diagnosis
Ct = Cost of all treatment
CCD [C + C ]/CCD dt = .
Table 1: Parameter assumptions and data sources
Description Assumption/Parameter Source
Exchange rate 1 USD = ZMK4512.51
(All costs are presented in US$)
http://www.oanda.com
(average March to November 2005)
Discount rate 5% MOH Planning Unit
Overhead costs 15%
(Of district recurrent expenditure)
District Health Office (DHO)
Personnel costs Gross earnings
(Collected from central level, allocated based on 
malaria utilisation)
MOH/DHO
Cost of drugs and tests
AL 2.45 USD NMCC, (weighted average cost per person/course including 
storage and distribution costs).
SP 0.18 USD
Quinine 0.84 USD
RDT 1.50 USD NMCC (excludes personnel and capital costs).
Microscopy 1.00 USD
Laboratory utilisation 60% Expert opinion
Sensitivity of the diagnostic techniques
Clinical 100%, 90% Current study data from clinical sites and published literature 
[13,14].
Microscopy 91% Colin et al 2002 [15]
RDTs 95.4% Guthman et al 2002 [16]
Mendiratta et al 2006 [17].
Malaria prevalence by district*
Chingola 18.8% NMCC 2005 [9]
Chongwe 22.0% NMCC 2005 [9]
Kalomo 26.3% NMCC 2004
Kabwe 10.6% NMCC 2005 [9]
The malaria prevalence above refers to the proportion of people with detectable malaria parasites in their peripheral blood, approximated from the 
average annual parasite prevalence surveys among the 2–9 years old in each district.Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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CCD = Number of cases correctly diagnosed.
The incremental cost per additional case correctly diag-
nosed was calculated based on the changes in the costs
and effects of moving from the strategy that costs less per
patient diagnosed to the next alternative in order of the
rank of costs per patient. Thus:
Sensitivity analysis
Simple (one-way) sensitivity analysis was used on param-
eters that as demonstrated elsewhere [12,18,19] might
impact on the study results. These include; discount rate,
the sensitivity of clinical diagnosis, accuracy of diagnostic
tests, personnel costs, allocation factor for shared costs
and prices of RDTs and AL. Personnel costs were chosen
because they were a major cost component in all the facil-
ities. When performing sensitivity analysis, ACER values
were recalculated maintaining the observed drug prescrip-
tion practices.
Data entry and analysis
Morbidity data was entered and analysed in STATA ver-
sion 8. Cost data was entered and analysed in excel fol-
lowing the principles of cost analysis [12,19]. The cost of
malaria drugs for treatment was estimated from the unit
cost of antimalarials and the number of patients treated
by each type of antimalarial. The potential costs of scaling
up the most cost effective strategy in the entire district of
analysis were based on the already existing structures and
resources.
Results
Summaries from morbidity data
During the study period, (March to November 2005),
more than 23,600 suspected malaria visits were recorded
at the 12 out-patient clinics in the four districts. Of these
attendances, 6520 (28%) were reported at clinical facili-
ties, 10460 (44%) at microscopy facilities and 6685
(28%) at the RDTs facilities. Table 3 shows the aggregated
diagnostic results for the entire study period per facility.
Variations on total visits across facilities are explained
ICER change in cost change in cases correctly diagnosed =           /
Table 2: Facility visits and diagnostic results
District Health Facility Total Visits Diagnostic Result % found Negative of total 
visits
Diagnostic Method
Positive Uncomplicated Positive Severe Negative
Chingola
(Urban)
Kalilo 409 378 29 2 0.49 Clinical
Kabundi 3084 1552 15 1517 49.19 Microscopy
Kasompe 1187 281 6 900 75.82 RDT
Chongwe
(Rural)
Chinyunyu 1430 1367 11 52 3.64 Clinical
Chongwe 3338 1130 46 2162 64.77 Microscopy
Chalimabana 2634 928 35 1671 63.44 RDT
Kalomo
(Rural)
Kalonda 1020 1018 2 0 0.00 Clinical
Namwianga 1975 813 0 1162 58.84 Microscopy
Mukwela 874 263 1 610 69.79 RDT
Kabwe
(Urban)
Natuseko 3661 3003 21 637 17.4 Clinical
Makululu 2063 282 0 1781 86.33 Microscopy
Kawama 1990 216 1 1773 89.1 RDT
TOTAL 23665 11231 167 12267 51.84 -Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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partly by different catchment areas and levels of utilisa-
tion. Children under five years accounted for 51% of all
attendances.
Overall, regardless of diagnostic strategy, 51.84% (N =
12,267) were found not to have malaria. Another, 48.2%
(N = 11398) were found to have malaria. Of those found
with malaria, 98.5% were considered to be uncompli-
cated malaria while 1.5% (N = 167) were diagnosed with
severe malaria.
Effectiveness Analysis: Cases Correctly Diagnosed (CCD)
Table 4 summarises the estimation of CCD aggregated by
each diagnostic technique.
Clinical diagnosis of malaria was found to have the lowest
accuracy (24%) in diagnosing malaria when compared to
either microscopy or RDT methods, table 4 refers. The
proportion of false positives in clinical diagnosis was
more than those by microscopy and RDT strategy. The
RDT diagnosis led to less false negatives (<1%), while
clinical and microscopy were responsible for 1.1% and
1.8% false negatives respectively. A lower proportion of
false negatives are desirable in malaria diagnosis due to
the negative consequences of leaving malaria untreated.
A positive malaria case diagnosed microscopically had a
53% certainty that it was a true positive malaria case,
while a negative result was 3% likely to be a true malaria
case (false negative). Thus a negative malaria result diag-
nosed by microscopy would be more reliable than a posi-
tive result. The average accuracy of microscopy in
diagnosing malaria patients was found to be about 79%
(see 4 below). On the other hand, a positive malaria result
on RDT had a 70% chance of being a true malaria case,
while a negative result had a 2% likelihood of being a true
malaria case. Both the positive and negative likelihood
ratios of the RDT indicate that a malaria test result on RDT
is more reliable. Among the patients diagnosed by RDT,
only 8% were false positives.
Cost Estimates by Diagnosis Strategy
The costs of malaria diagnosis were grouped into five
main categories. These were personnel, capital costs, diag-
nostic technique and overheads. In the first step, treat-
ment costs were not included. These categories were
further specified for each diagnostic strategy and facility.
All costs are expressed in USD as shown in table 4, 5, 6.
Personnel costs were an important cost component
among the three strategies. While clinical and RDT per-
sonnel costs were similar at about USD 2.3 – 2.4 per visit,
microscopy personnel costs were found to be the highest
at USD 5.3 per visit (with considerable variation across
facilities). Routine capital costs were also similar for clin-
ical and RDT strategies but for microscopy they were 7
times higher. There was no cost associated to the diagnos-
tic technique for clinical strategy, USD 1.2 for microscopy
and higher for RDT at USD 1.6. Overheads were lowest in
the clinical strategy and highest in the microscopy strat-
egy.
Overall, the unit cost per visit was USD 2.7, USD 8.2 and
USD 4.7 for clinical, microscopy and RDT strategy respec-
tively. A relevant finding of this study is that in general,
health workers do not base the drug prescription on the
test result (for both laboratory and RDTs) as shown in fig-
ure 1.
For this reason, the cost per case diagnosed (total cost of
diagnosis/visits) was estimated using the total cost while
excluding treatment costs at first. Then later, when esti-
Table 3: Summary of average effectiveness of each strategy
Strategy Clinical Microscopy RDT
Total Visits 6520 10460 6685
Test Results
Found Positive (%) 5829 3838 1731
Found Negative (%) 691 6622 4954
Estimations of Accuracy (refer to methods)
True Positives 977 1866 1186
False Positives 4852 1972 545
True Negative 621 6237 4896
False Negative 70 186 58
Sensitivity (%)- input 90 90.9 95.3
Specificity (%)- output 11.3 76.5 90
Cases correctly diagnosed 1598 8303 6082
Accuracy (%) 24.5 79.4 91.0
Estimations of Reliability
Likelihood ratio positive 1.1 3.9 9.5
Likelihood ratio negative 0.6 0.1 0.1
Positive post-test probability 17% 53% 70%
Negative post-test probability 10% 3% 2%Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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mating the cost per case correctly diagnosed, treatment
costs were included in the total costs. In order to show the
difference between the observed practice of treating all as
observed in the study and a scenario where only cases that
are found positive were treated, the results are presented
using these two scenarios for treatment.
Table 5 below shows the costs and cost effectiveness ratios
for the three strategies. The average cost per patient under-
going malaria diagnosis was found to be lowest in the
clinical strategy (USD 2.7). The cost of microscopy was
three times the cost of clinical diagnosis and twice the cost
of the RDT strategy per patient diagnosed.
The potential savings on treatment if only cases found
positive are treated were zero for clinical, 56% for micros-
copy and 59% for RDT strategy respectively. This shows
that using clinical diagnosis may not lead to cost savings
on treatment, while using microscopy or RDT result for
treatment prescription has the potential to maximise sav-
ings on antimalarial drugs.
The ACER per case correctly diagnosed was highest in the
clinical strategy, followed by microscopy and least in the
RDT strategy. As expected, considering the two situations
described above (treatment as observed and treatment if
only found positives are treated), the ACER under the
observed treatment pattern (row l) was higher than when
only cases found positive are treated (row m), again
except for the clinical strategy. Table 6 shows the incre-
mental cost-effectiveness ratios for the three strategies.
Table 4: Cost profiles per diagnostic strategy
Clinical Microscopy RDT
a. Catchment 28528 82434 35260
b. Visits 6520 10460 6685
Utilisation rate (b/a) 0.23 0.16 0.19
Costs (US$)
Diagnostic Technique 0 11,611 10,302
Personnel 14,899 55,347 15,828
Personnel (extra time) 0 0 490
Capital (Routine – not unique to malaria) 678 7,136 625
Capital (Laboratory- diagnosis specific) 0 1,054 -
Overheads 2,287 10,956 4,293
Total Cost 17,864 86,103 31,508
Unit cost per type of resource
Diagnostic Technique 2.3 1.1 1.5
Personnel 0.1 5.3 2.4
Personnel (extra time) 0 0 0.1
Capital (Routine) 0 0.7 0.1
Capital (Laboratory*) 0 0.1 -
Overheads 0.4 1 0.6
Cost per visit 2.7 8.2 4.7Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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Incremental analysis was estimated using as baseline the
least cost-effective strategy (clinical) and moving to either
microscopy or RDT. Given the differences in the number
of patients seen by each strategy, cost and effect have been
expressed per patient. Hence, as shown in table 6 above,
the clinical strategy was used as baseline. When consider-
ing only diagnoses costs, the incremental cost required per
additional case correctly diagnosed was found to be lower
for RDT (USD 3) than microscopy (USD 10). In other
words, microscopy should be eliminated by extended
dominance [20]. When considering the incremental cost
per additional case correctly diagnosed and treated, which
was considered as the baseline ICER results (*), values
reduced from USD 3 to USD 2.6 for RDT and from USD
10.2 to USD 9.6 for microscopy as shown in table 6. These
decreases are due to the fact that, in comparison to clinical
diagnosis, treatment patterns with RDTs and Microscopy
generates some savings on antimalarials.
Sensitivity Analysis
Overall, the parameters that had the strongest effect on
reducing RDT efficiency against the alternatives were
increases in RDT and AL costs, reducing accuracy of the
RDT, an increase in the malaria allocation factor (malaria
visits as a proportion of all OPD visits and increasing per-
sonnel costs. On the other hand, the parameters that
improve even more the position of RDT were lower unit
costs of RDT and AL and reduced malaria related visits.
Discussion
In different epidemiological settings and variable contexts, the
clinical diagnosis of malaria was not a cost effective strategy for
malaria diagnosis in the four districts in Zambia, if cases cor-
rectly diagnosed were to be maximised. The RDT was found to
be cheaper at correctly diagnosing malaria (USD 6.5) than
microscopy (USD 11.9) and clinical (USD 17.1) in routine
outpatient clinics. This study is the first in Zambia to demon-
Table 5: Costs and cost-effectiveness ratios
Clinical Microscopy RDT
a. Visits 6520 10460 6685
Diagnosis Costs 
b. Cost of Diagnosis (prior treatment) 17,864 86,103 31,508
c. Cost/patient diagnosed (b/a) 2.7 8.2 4.7
Treatment Costs
d. Treatment costs (All treated as observed in study*) 9,422 12,708 7,918
e. Treatment costs (If only positive treated**) 9,429 5,590 3,226
Total Costs
f. Total cost (b+d)* 27,286 98,811 39,426
g. Total cost (b +e)** 27,293 91,693 34,734
h. Cost/patient diagnosed and treated (f/a)* 4.2 9.4 5.9
i. Cost/patient diagnosed and treated (g/a)** 4.2 8.8 5.2
Total Effectiveness
j. Number of cases correctly diagnosed 1598 8303 6082
k. Proportion of cases correctly diagnosed (j/a) 0.25 0.79 0.91
Average Cost Effectiveness Ratios (ACER)
l. Total cost/cases correctly diagnosed (f/j)* 17.1 11.9 6.5
m. Total cost/cases correctly diagnosed (g/j)** 17.1 11.0 5.7Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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strate the cost effectiveness of malaria diagnosis in the era of
ACTs as treatment for uncomplicated malaria. In incremental
analysis, the cost per additional case correctly diagnosed was
found to be 70% (USD 7) lower for RDT than microscopy. It
is more likely that policy makers would opt to implement
RDTs given that they require less additional resources but also
yield more correct diagnoses than microscopy, holding all
other factors constant.
Microscopy malaria diagnosis in the peripheral health
centres was less effective than expected (as compared by
its assumed sensitivity). These findings challenge the
notion that microscopy is the gold standard for malaria
diagnosis [21,22]. This study proposes that microscopy is
only gold standard when performed by expert micro-
scopists under ideal conditions. The proportion of RDT
false positives was found to be lowest among the three
strategies (8%). These findings are within the range of the
10% false positives expected on HRP-2 based RDT [23]. It
is therefore important to observe here that in terms of
reducing false positives (and in turn reduce expenditure
on unnecessary drugs) RDTs were more effective than
microscopy and much more than clinical diagnosis.
The diagnostic test result did not seem to influence the
decision to either treat or not treat with an antimalarial. It
was found that almost 87% of all facility visits were pre-
scribed antimalarials regardless of the malaria test result.
However, an interesting observation was that the test
result influenced the type of antimalarial, which was pre-
scribed to a patient. Those cases that were more likely to
have malaria (found positive) had a higher chance of
being prescribed AL. Based on these observations; this
study does not fully support the proposition that malaria
diagnostic techniques do not guide treatment decision.
This study demonstrated that there are cost savings
(although moderate) on treatment associated to a specific
diagnostic test. This in spite of the treatment patterns dis-
cussed above. Moreover, assuming a situation where a
diagnostic test result could strongly influence the decision
to prescribe or not an antimalarial, microscopy and RDT
diagnosis would have the potential of saving 56% and
59% respectively on antimalarials. In Malawi, it was
found that using microscopy could lead to about USD14,
000 savings on drugs annually in one hospital [24]. In the
Zambian context, it would be interesting to find out if the
prescription trends found in the facilities (in this study)
are similar in hospitals. This would provide an idea of the
potential savings in antimalarials at that level of care.
Apart from the obvious effect on costs, irrational drug use
may lead to stock outs of antimalarials at a time when
they are most needed. Furthermore, the increase in drug
pressure in the population could increase the probability
of drug resistance to ACTs developing early [25,26]. The
potential negative health effects this may have cannot be
underestimated.
Table 6: Incremental cost-effectiveness ratios
Incremental Cost Effectiveness Ratios Clinical Microscopy RDT
Cost/patient diagnosed 2.7 8.2 4.7
Effectiveness per case diagnosed 0.25 0.79 0.91
Moving from clinical to either microscopy or RDTs
Incremental costs - 5.5 2.0
Incremental effects - 0.54 0.66
ICER 10.2 3.0
Cost/patient diagnosed and treated* 4.2 9.4 5.9
Effectiveness per case diagnosed 0.25 0.79 0.91
Moving from clinical to either microscopy or RDTs
Incremental costs - 5.2 1.7
Incremental effects - 0.54 0.66
ICER (USD) 9.6 2.6Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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A study conducted by Rolland et al [18] in a hypothetical
epidemic situation found the cost per true malaria case
detected by RDT was USD 19.87 while for clinical diagno-
sis it was USD 18.4 at 25% prevalence. Rolland et al used
a hypothetical epidemic situation and a different outcome
measure hence making comparisons with this study diffi-
cult. However, in Thailand a study by Buolombai et al
[27] compared the cost effectiveness of microscopy to two
types of RDTs (OptiMAL and ICT) from a societal perspec-
tive. Microscopy was found to cost more per true falci-
parum positive case detected than the two RDTs (446.75
Baht vs 282.40 Baht and 343.56 Baht). Since this study is
comparable in terms of using a longer data collection
period and actual malaria setting (except for the costing
perspective), the findings may be more comparable to the
Zambian situation than the Rolland et al study. However,
none of these studies compared all the three interventions
as conducted in this study.
Thus when assessing the cost effectiveness of malaria diag-
nosis, differences in methodologies and patient popula-
tion characteristics are very important and need to be
explored more. Additionally, this study found that health
workers might have a role to play in modifying the poten-
tial effectiveness of a test through their actual practice
when diagnosing malaria. Hence future research should
explore these areas and the extent to which they act as a
confounding factor.
None of the parameters used in the sensitivity analysis
changed the position of the RDT as the most cost effective
strategy at correctly diagnosing malaria. However, some
parameters increased the costs of cases correctly diag-
nosed, while others reduced the costs of case correctly
diagnosed.
This study contributes to new knowledge on the econom-
ics aspects of malaria case management. This is relevant
since economic evaluations on malaria interventions,
especially in Zambia, are scarce. The results of this analysis
will serve to inform policy makers on which alternatives
will be most efficient in reducing malaria misdiagnosis by
taking into account both the costs and effects of each strat-
egy.
Strengths
This study was conducted within the actual malaria con-
text using field-based data in a malarious population. The
advantage of field-based data is that it incorporates the
inherent differences in practice, settings and seasons,
which cannot be found in hypothetical or trial settings.
The observation period was long enough to account for
seasonal variations in malaria transmission which affects
the expected patient visits and the prevalence of malaria at
OPD. Variations in the study site settings provided an
understanding into how facility utilisation, staffing levels,
capital endowment and other capacities affect the cost of
malaria diagnosis. The study also looked at all the possi-
ble outcomes of a diagnostic test as opposed to just
focussing on the positive malaria cases. Sensitivity analy-
sis on variables used in the estimations of costs and effects
provided insights into how the study findings would
change across other settings and contexts. This not only
helped to show the robustness of the results but also
showed how costs of malaria diagnosis may vary depend-
ing on the prevailing situation in an area being consid-
ered.
Limitations
One of the main limitations of the study is that the out-
come measure used in the analysis is an intermediate one.
Thus it has been assumed that cases correctly diagnosed
may be linked to improved final outcome (recovery from
disease). However, the link between correctly diagnosing
a case, an optimal clinical management of the patient and
a satisfactory health outcome (after treatment) may be dif-
ficult to prove, without a close patient follow up. Thus
within the realm of this study, it was not possible to esti-
mate the link between incorrectly diagnosing a patient
and the final clinical outcome (especially false negatives).
This is a potential area for further research.
The use of a societal perspective is usually recommended
in economic evaluations. However, in this study the pro-
vider perspective was used because malaria services are
provided free of charge and the indirect patient costs
would be similar across the four districts.
The use of facility registers may raise concerns with the
reliability of the data due to potential errors in the data
recording at facility level. Nonetheless, the use of a three
Treatment characteristics Figure 1
Treatment characteristics.Cost Effectiveness and Resource Allocation 2009, 7:5 http://www.resource-allocation.com/content/7/1/5
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level supervision system (facility, district and national
level) during the entire 8 months ensured completeness
and consistency in the data collection process.
Another limitation of the study arose from difficulties in
defining the sensitivity of clinical diagnosis, as this can be
very subjective. Further, clinical diagnosis does not allow
for assessing the extent of to which patients should be sus-
pected to have clinical malaria. However, other studies
conducted elsewhere, have shown similar sensitivity val-
ues as the estimates found in this study [13,14].
Conclusion
This study has shown that RDTs are the most cost effective
method at correctly diagnosing malaria in lower level
health facilities in Zambia when compared to clinical and
microscopy strategies. However, the amount of cost sav-
ings in drugs was limited by the health worker treatment
practices. The incremental cost per case correctly diag-
nosed and treated was USD 2.6 for RDT compared to USD
9.6 for microscopy. Thus RDT would be much cheaper to
scale up than microscopy. The findings were robust to
changes in assumptions and parameters. These findings
could be relevant for transferability to low-income coun-
tries where malaria is endemic, AL is being used for first
line treatment of malaria and microscopy diagnostic serv-
ices are not readily available.
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